COMP <GO>
A vs UNH // 10Y YIELD & FRED MACRO BETA
Agilent Technologies Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: A 8
— UNH 7
▲ 10Y YIELD & FRED MACRO BETA LEADER: A
LAST: $174.87 (-3.47%) • MKT CAP: $51.07B
macro-sensitivity
0.91
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (A VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | A | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.40% | 88.57% | -36.17 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.30% | 11.47% | +3.83 | A | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.4x | 16.4x | +11.95 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.26% | 6.48% | -4.22 | UNH | /fcf-yield <GO> |
| Operating Margin | 21.30% | 4.82% | +16.48 | A | /operating-margins <GO> |
| Net Profit Margin | 18.80% | 3.14% | +15.66 | A | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | 6.46% | +0.24 | A | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.55% | 2.28% | -1.73 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.50 | 3.12 | +3.38 | A | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | A | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.74% | -0.14 | A | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 56.0 | -1.14 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.91 | 0.33 | +0.58 | A | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.5x | 17.1x | +19.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $51.07B | $364.66B | -$313.59B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | A REV | UNH REV | A GROSS % | UNH GROSS % | A FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.95B | $447.57B | 52.4% | 88.7% | $1.15B | $16.07B |
| FY 2024 | $6.51B | $400.28B | 54.3% | 88.3% | $1.37B | $20.70B |
| FY 2023 | $6.83B | $371.62B | 44.0% | 89.6% | $1.46B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
A // BETA 0.91
UNH // BETA 0.33